sorafenib has been researched along with Synovioma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrari, S; Paioli, A; Palmerini, E | 1 |
| Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E | 1 |
| Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J | 1 |
| Basso, U; Bertuzzi, A; Brunello, A; Santoro, A | 1 |
| Guo, W; Ji, T; Li, DS; Li, X; Peng, CL; Qu, HY; Ren, T; Tang, S; Tang, XD; Yan, TQ; Yang, Y | 1 |
1 review(s) available for sorafenib and Synovioma
| Article | Year |
|---|---|
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
4 other study(ies) available for sorafenib and Synovioma
| Article | Year |
|---|---|
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sarcoma, Synovial; Sorafenib; Tetrahydroisoquinolines; Trabectedin | 2014 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pneumothorax; Sarcoma, Ewing; Sarcoma, Synovial; Sorafenib; Wilms Tumor; Young Adult | 2015 |
Sorafenib is active on lung metastases from synovial sarcoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sarcoma, Synovial; Sorafenib; Time Factors; Treatment Outcome | 2009 |
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Humans; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Retinoblastoma Protein; S Phase; Sarcoma, Synovial; Signal Transduction; Sorafenib | 2009 |